Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 1

Interventions

pembrolizumab 9Drug Therapy 9Bevacizumab 9Radiotherapy 8Carboplatin 8Oxaliplatin 7Cyclophosphamide 7Surgical Procedures, Operative 6Cisplatin 6Capecitabine 6tislelizumab 5Paclitaxel 5Fluorouracil 5Docetaxel 5Control Groups 5Nivolumab 4Immune Checkpoint Inhibitors 4Gemcitabine 4Endoscopic Mucosal Resection 4sintilimab 3fludarabine 3Trastuzumab 3Pemetrexed 3Neoadjuvant Therapy 3Leucovorin 3Laparoscopy 3Irinotecan 3Injections 3Hematologic Tests 3HMPL-013 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × OTHER_GOV × fosaprepitant × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡